Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences dismisses MaloneBailey, engages RBSM as new auditor

Neutral Impact 3 of 5 leadership Written later

Greenwich LifeSciences dismissed MaloneBailey LLP as its independent registered public accounting firm and engaged RBSM LLP to audit its financial statements for the year ended December 31, 2023. The filing states that MaloneBailey's reports for 2021 and 2022 contained no adverse opinion, disclaimer, or qualification, but notes material weaknesses in internal control over financial reporting disclosed in prior filings. The change is administrative in nature, though the disclosed material weaknesses are relevant to shareholders.

Key points

  • Audit committee approved the dismissal of MaloneBailey LLP and the engagement of RBSM LLP on February 14, 2024
  • MaloneBailey was informed of its dismissal on February 15, 2024, effective immediately
  • MaloneBailey's reports for 2021 and 2022 had no adverse opinion, disclaimer, or qualification
  • Material weaknesses in internal control were disclosed in the 2022 and 2021 Form 10-K filings and in 2023 Form 10-Q filings; no disagreements with MaloneBailey are reported

The filing

CompanyGreenwich LifeSciences, Inc. (GLSI)
Form8-K, current report
Filed with the SECFeb 20, 2024, 4:15 PM ET
Accession number0001493152-24-007223

Items reported: 4.01 Auditor Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 20, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.